1Jemal A,Siegel R,Ward E,et al.Cancer statistics,2006[J].CA Cancer J Clin,2006,56(2):106-130.
2Galvez BG,Matias-Roman S,Yanez-Mo M,et al.ECM regulates MT1-MMP local-ization with β1 or αvβ3 integrins at distinct cell compartments modulating its internalization and activity on human endothelial cells[J].J Cell Biol,2002,159(3):509-521.
3Hsia DA,Mitra SK,Hauck CR,et al.Differential regulation of cell motility and invasion by FAK[J].J Cell Biol,2003,160(5):753-767.
4周侨.肿瘤[M]//李玉林.病理学.7版.北京:人民卫生出版社,2008:87.
5Kim MD,Seung D,Yoon-La MD,et al.High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis[J].Hum Pathol,2006,37(5):906-911.
6Belotti P,Paganoni L,Manenti A,et al.Matrix metalloproteinases(MMP9 and MMP2) induce the release of vascular endothelial growth factor by ovarian carcinoma cells:implications for ascites formation[J].Cancer Res,2003,63(3):5224-5231.
7Rauvala U,Puistola T,Trpenniemi H,et al.Gelatinases and their tissue inhibitors in ovarian tumors;TIMP-1 is a predictive as well as a prognostic factor[J].Gynecol Oncol,2005,99(6):656-662.
8Fishman DA,Liu Y,Ellerbroek SM,et al.Lysophosphatidic acid promotes matrix metalloproteinase activation and MMP-dependent invasion in ovarian cancer cells[J].Cancer Res,2001,61(4):3194-3201.
9Lin CK,Chao TK,Yu CP,et al.The expression of six biomarkers in the four most common ovarian cancers:correlation with clinic pathological parameters[J].APMIS,2009,117(3):162-175.
10Kim DS,Jeon OH,Lee HD.Integrin αvβ3-mediated transcrip tional regulation of TMP-1 in a human ovarian cancer cell line[J].Biochem Biophys Res Commun,2008,377(2):479-483.
2[3]Evan G,Litflenood T.Amatter of life and cell death[J].Science,1998,281(5381):1317-1322.
3[4]Fawi Aoudjit,Kristiuna Vuori.Integrin siganaling inhibits paclitaxel-induced apoptosis in breast callcer cells[J].Oncogene,2000,20:4995-5004.
4[5]Goldberg I,Davidson B,Reich R,et al.Alpha v integrin expression is a novel marker of poor pmghosis in advanced-stage ovarian carcinoma[J].Clin Cancer Res,2001,7(12):4073-4079.
5OZOLS R F. Future directions in the treatment of ovarian cancer [ J ]. Semin Oncol, 2002, 29 (Suppl 1): 32.
6EISENHAUER E, DANCEY J. Impact of new non -cytotoxics in the treatment of ovarian cancer [J].IntJ Gynecol Cancer, 2001, 11 (Suppl 1): 68.
7BROWN M R, BLANCHETTE J O, KOHN E C.Angiogenesis in ovarian cancer [J]. Res Clin Obstet Gynaecol, 2000, 14 (6): 901.
8SCAPPATIOCI F A. Mechanisms and future directionsfor angiogenesis-based cancer therapies [J ]. J Clin Oncol, 2002, 20 (18): 3906.
9SEGURA I, SERRANO A, DE BGG, et al.Inhibition of programmed cell death impairs in vitro vascular-like structure formation and reduces in vivo angiogenesis [J]. FASEBJ, 2002, 16 (8): 833.
10THIJSSEN V L, BRANDWIJK R J, DINGS R P,et al. Angiogenesis gene expression profiling in xenograft models to study cellular interactions [J ].Exp Cell Res, 2004, 299 (2): 286.
